Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission

doi:10.1016/0022-3956(91)90021-2

Journal of Psychiatric Research

Volume 25, Issue 4, 1991, Pages 169-177

https://doi.org/10.1016/0022-3956(91)90021-2 Get rights and content

Abstract

Sleep EEG and the nocturnal secretion of cortisol and testosterone in 12 male patients (mean age 46.4±11.26 years) with major endogenous depression were investigated concomitantly during acute depression, before treatment and after recovery and drug cessation. Testosterone concentration increased after remission, while cortisol secretion decreased. Sleep EEG disturbances remained unchanged in remitted patients. The data suggest that a blunted testosterone and an elevated cortisol secretion are state markers of acute depression, which normalize independently from sleep structure. An interaction between the hypothalamic-pituitary-gonadal axis and the limbic- hypothalamic-pituitary-adrenocortical axis appears likely.

References (33)

C.J. Lauer et al.
From early to late adulthood: changes in EEG sleep of depressed patients and healthy volunteers
Biological Psychiatry
(1991)
K.E. Nikolarakis et al.
Corticotropin releasing factor (CRF) inhibits gonadotropin-releasing hormone (GnRH) release from superfused rat hypothalami in vitro
Brain Research
(1986)
A. Steiger et al.
Sleep EEG and nocturnal secretion of cortisol and growth hormone in male patients with endogenous depression before treatment and after recovery
Journal of Affective Disorders
(1989)
M.E. Thase et al.
Nocturnal penile tumescence is diminished in depressed men
Biological Psychiatry
(1988)
O.F.X. Almeida et al.
Evidence for the involvement of endogenous opioids in the inhibition of luteinizing hormone by corticotropin-releasing factor
Endocrinology
(1988)
U. von Bardeleben et al.
Nocturnal sleep-endocrine effects of cortisol infusions in normal controls
Neuroendocrinology Letters
(1988)
C.L. Ehlers et al.
The effects of corticotropin releasing factor (CRF) and growth hormone releasing factor (GRF) on sleep and activity in rats
Neuroendocrinology
(1986)
J.I. Evans et al.
Concentrations of plasma testosterone in normal men during sleep
Nature
(1971)
F. Holsboer
Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity
European Archives of Psychiatry and Neurological Sciences
(1989)
F. Holsboer et al.
Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man
Neuroendocrinology
(1988)

D.B. Jarrett et al.

Reduced cortisol latency in depressive illness

Archives of General Psychiatry

(1983)

J.B. Knowles et al.

Age-related changes in sleep in depressed and healthy subjects. A meta-analysis

Neuropsychopharmacology

(1990)

D.J. Kupfer

Application of EEG sleep for the differential diagnosis and treatment of affective disorders

Pharmakopsychiatrie

(1978)

L. de Lacerda et al.

Integrated concentration and circadian variation of plasma testosterone in normal men

Journal of Clinical Endocrinology and Metabolism

(1973)

A.J. Levitt et al.

Total and free testosterone in depressed men

Acta Psychiatrica Scandinavica

(1988)

P. Linkowski et al.

24-Hour profiles of adrenocorticotropin, cortisol and growth hormone in major depressive illness: effect of antidepressant treatment

Journal of Clinical Endocrinology and Metabolism

(1987)

Cited by (52)

Antidepressants’ effects on testosterone and estrogens: What do we know?
2021, European Journal of Pharmacology
Citation Excerpt :
Studies in animals and primates suggest that HPA axis dysregulation and stress reactivity are present in depression, and antidepressants can facilitate normalization of the HPA axis function. Therefore, given that the HPA and HPG axis functions interact, there may be a common neuroendocrine response to antidepressant treatment (Steiger et al., 1991). However, the effect of antidepressants on the central regulation of the HPG axis still remains an unexplored issue.
Various antidepressants are commonly used to treat depression and anxiety disorders, and sex differences have been identified in their efficacy and side effects. Steroids, such as estrogens and testosterone, both in the periphery and locally in the brain, are regarded as important modulators of these sex differences. This review presents published data from preclinical and clinical studies that measure testosterone and estrogen level changes during and/or after acute or chronic administration of different antidepressants. The majority of studies show an interaction between sex hormones and antidepressants on sexual function and behavior, or in depressive symptom alleviation. However, most of the studies omit to investigate antidepressants’ effects on circulating levels of gonadal hormones. From data reviewed herein, it is evident that most antidepressants can influence testosterone and estrogen levels. Still, the evidence is conflicting with some studies showing an increase, others decrease or no effect. Most studies are conducted in male animals or humans, underscoring the importance of considering sex as an important variable in such investigations, especially as depression and anxiety disorders are more common in women than men. Therefore, research is needed to elucidate the extent to which antidepressants can influence both peripheral and brain levels of testosterone and estrogens, in males and females, and whether this impacts the effectiveness or side effects of antidepressants.
Alcohol consumption and incidence of sleep disorder: A systematic review and meta-analysis of cohort studies
2020, Drug and Alcohol Dependence
Citation Excerpt :
Therefore, alcohol has an extensive and diverse effect on our neurochemical systems, which might explain the high‐frequency EEG activity after drinking (Pandi-Perumal et al., 2015; Landolt et al., 1996) and the effect of drinking on sleep. Besides mechanisms discussed above, alcohol might associate with Circadian Rhythm Sleep‐Wake Disorders (Zhou et al., 2003; Kühlwein et al., 2003) and endocrine system, which might be associated with menstrual-related changes and affect subjective and objective sleep disorders in female drinkers (Manber and Armitage, 1999; Steiger et al., 2020). There are several strengths in our meta-analysis.
To investigate the association between alcohol consumption and incidence of sleep disorder.
PubMed, EMBASE and OVID were searched systematically until March 2020 for cohort studies quantitatively investigating the effect of alcohol on incident sleep disorder. We conducted a random-effects meta-analysis to calculate the summary ORs (odds ratios) and 95 %CIs (confidence intervals) on the incidence of sleep disorder in relation to alcohol consumption.
The pooled analysis of eleven included cohort studies demonstrated that general drinking was significantly associated with incidence of sleep disorder (OR:1.37, 95 %CI:1.22,1.54,I² = 0.0 %) while heavy drinking was not (OR:1.22, 95 %CI:0.94,1.60, I² = 81.1 %). (general drinking (women <24 g/day; men <48 g/day; < 4 times/week), heavy drinking (women ≥24 g/day; men ≥48 g/day; ≥ 4times/week)).
Findings from the present systematic review and meta-analyses showed that there was no evidence that alcohol consumption diminished sleep problems, and some evidence that general drinking might increase the sleep problems, but further study is necessary.
Electroencephalographic sleep profiles in treatment course and long-term outcome of major depression: Association with DEX/CRH-test response
2004, Journal of Psychiatric Research
Altered electroencephalographic (EEG) sleep patterns are among the most prominent neurobiological findings in depression. Several of these alterations have been suggested to be associated with an unfavorable long-term outcome. However, the impact of pathological sleep parameters on a more recurrent course of illness or vice versa still warrants clarification. Underlying mechanisms may involve systems known to be related to both sleep regulation and long-term course of depression such as the hypothalamic-pituitary-adrenocortical (HPA) axis. Thus, EEG sleep profiles of patients with depression were examined to determine whether (1) the retrospective clinical course of depression, and (2) the prospective long-term outcome in follow-up are associated with EEG sleep parameters. To elucidate related mechanisms HPA system functioning was evaluated by using the combined DEX/CRH test. Fifteen patients with affective disorders who participated in an earlier controlled antidepressant treatment study over 6 weeks were consecutively enrolled in an exploratory follow-up study. The retrospective analysis revealed that during the acute state of depression predominantly sleep continuity measures were associated with the number of previously experienced episodes. While this relation disappeared during treatment and did not correlate with the prospective course, decreased slow wave sleep variables especially in the first sleep period and increased rapid eye movement density were predictive for the occurrence of recurrences in follow-up and, hence, probably reflect more trait-like markers. Additionally, EEG sleep variables unfavorable for long-term outcome were related to excessive stress hormone response in the DEX/CRH-test. These disturbances may reflect important mechanisms responsible of causing and maintaining the disease process of depression.
Sub-chronic treatment with an extract of Hypericum perforatum (St John's wort) significantly reduces cortisol and corticosterone in the rat brain
2004, European Neuropsychopharmacology
Extracts of Hypericum perforatum (HP) have been shown to be effective for the treatment of mild to moderate depression. Its mode of action has not been fully elucidated. An increase in plasma and cerebrospinal fluid (CSF) cortisol is frequently observed in depression. Studies have suggested that HP might alter brain cortisol and corticosterone through its effect on multidrug transporter glycoprotein (Pgp). We investigated the effect of sub-chronic treatment with an extract of HP (LI 160) on brain levels of corticosterone and cortisol in the rat. Results show that HP significantly reduced corticosterone and cortisol in brain frontal cortex tissue. These changes are not reflected in serum. These findings may be important with respect to HPs mode of antidepressant action.
Andropause and psychopathology: Minor symptoms rather than pathological ones
2003, Psychoneuroendocrinology
This study examined the psychological symptomatology of men diagnosed with andropause and the association between calculated free testosterone (T) and depressed mood, anxiety and quality of life. Subjects were 153 men, aged 50–70 years, who participated in a screening of andropause. Total testosterone, FSH, LH and SHBG levels were measured. Depressed mood was assessed with the Carroll Rating Scale, anxiety with the “anxiety-insomnia” dimension of the General Health Questionnaire, and quality of life with the World Health Organisation Quality of Life questionnaire. The results showed that levels of free T decreased with age, whereas FSH and LH increased. Carroll Rating Scale scores were higher among hypogonadal subjects, but the mean score was low and not pathological. A negative correlation was observed between severity of depression as assessed by the Carroll Rating Scale and free T levels. However, subjects with a significant score on this scale did not exhibit different free T levels compared to subjects with a non-significant depressive score. Anxiety and quality of life did not differ between hypogonadal and eugonadal subjects. The present study therefore suggests that andropause is not characterised by specific psychological symptoms, but may be associated with “depressive symptoms” that are not considered as pathological.
Hypothalamic–pituitary diseases and erectile dysfunction
2021, Journal of Clinical Medicine

View all citing articles on Scopus

^☆: Parts of this study were presented at the XVIth Congress, of Collegium Internationale Neuro- Psychopharmacologicum, Munich, 15–19 August 1988.

View full text

Sleep EEG and nocturnal secretion of testosterone and cortisol in patients with major endogenous depression during acute phase and after remission☆

Abstract

Biological Psychiatry

Brain Research

Journal of Affective Disorders

Biological Psychiatry

Evidence for the involvement of endogenous opioids in the inhibition of luteinizing hormone by corticotropin-releasing factor

Endocrinology

Nocturnal sleep-endocrine effects of cortisol infusions in normal controls

Neuroendocrinology Letters

The effects of corticotropin releasing factor (CRF) and growth hormone releasing factor (GRF) on sleep and activity in rats

Neuroendocrinology

Concentrations of plasma testosterone in normal men during sleep

Nature

Psychiatric implications of altered limbic-hypothalamic-pituitary-adrenocortical activity

European Archives of Psychiatry and Neurological Sciences

Effects of intravenous corticotropin-releasing hormone upon sleep-related growth hormone surge and sleep EEG in man

Neuroendocrinology

Reduced cortisol latency in depressive illness

Archives of General Psychiatry

Age-related changes in sleep in depressed and healthy subjects. A meta-analysis

Neuropsychopharmacology

Application of EEG sleep for the differential diagnosis and treatment of affective disorders

Pharmakopsychiatrie

Integrated concentration and circadian variation of plasma testosterone in normal men

Journal of Clinical Endocrinology and Metabolism

Total and free testosterone in depressed men

Acta Psychiatrica Scandinavica

24-Hour profiles of adrenocorticotropin, cortisol and growth hormone in major depressive illness: effect of antidepressant treatment

Journal of Clinical Endocrinology and Metabolism